AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for ...

In an industry that never stops moving, accepting and embracing change is a constant. In this installment of Agency Advice ...

AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

MADISON, Wis. -- A global biopharmaceutical company headquartered in North Chicago has announced the acquisition of Madison-based Nimble Therapeutics for $200 million. According to a press release ...

“Nimble is what we are going to try to be.” Nimbleness has given way to sharpness for Vance with his comments on higher education and the impact it is having on American society. “So much of ...

Instead, manager Dave Roberts said Monday, the team will be "nimble" with Ohtani's pitching workload. To that end, Roberts said it's "unlikely" that Ohtani will pitch during the Dodgers' opening ...

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments. The acquisition includes Nimble's ...